Search

Search Constraints

You searched for: Author/Creator Andreeff, Michael

Search Results

31. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL‐6/gp130/STAT3 Pathway. (27th May 2015)

32. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Issue 1 (2nd January 2019)

33. Outcomes in patients with newly diagnosed TP53‐mutated acute myeloid leukemia with or without venetoclax‐based therapy. Issue 19 (28th June 2021)

34. Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Issue 9 (2nd September 2018)

35. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy. Issue 12 (29th August 2016)

36. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Issue 3 (22nd September 2016)

37. Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients. Issue 11 (19th August 2020)

38. Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission. Issue 11 (15th January 2021)

39. Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia. Issue 8 (25th June 2016)

40. Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Issue 4 (2nd March 2015)